Nigeria’s capacity to generate essential genomic data for pharmaceutical productions that suit the medical needs of Africa’s genetic framework is gaining more impetus on investors’ growing interest in the development of local molecular medicine.
Apart from the business side of it, the inves
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
